Home > Dermatology > AAD 2019 > Late-Breakers > Serlopitant reduces pruritus associated with psoriasis

Serlopitant reduces pruritus associated with psoriasis

Presented By
Dr David Pariser, Pariser Dermatology Specialists Virginia, USA
Conference
AAD 2019

Although many physicians associate pruritus primarily with atopic dermatitis, it is also very common in psoriasis where the majority of patients (60-90%) suffer from itch [1].

"Patients consider pruritus one of the most important and troublesome symptoms of psoriasis, affecting their daily activities and emotional wellbeing,” said Dr David Pariser (Pariser Dermatology Specialists Virginia, USA) during his presentation of the trial. At present, treatments for psoriasis do not consistently alleviate associated pruritus. Serlopitant is an oral, once daily neurokinin-1 receptor antagonist that demonstrated significant reduction in pruritus in phase 2 studies in patients with chronic pruritus and prurigo nodularis [2]. In the present trial, the agent was assessed in patients with psoriasis and worst itch according to an NRS (WI-NRS) at baseline (score ≥ 7) [3]. Primary endpoint was the WI-NRS 4-point responder rate at week 8, and the secondary endpoint was the ...



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on